Associate Director, Cancer Pharmacology, Translational Research

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with R-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with R-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

As an Associate Director in the Cancer Pharmacology team within the Translational Research group, in the Biomedical Discovery Research Department, you will:

• Provide scientific and strategic leadership for RAS(ON) inhibitor programs by translating mechanistic insights in RAS biology into impactful pharmacology strategies and translational study plans.
• Lead, mentor, and develop a high-performing group of in-vivo scientists, fostering scientific excellence, innovation, and cross-functional collaboration.
• Drive the design, execution, and interpretation of in-vivo efficacy and PK/PD studies conducted internally and through external partners to advance oncology discovery and development programs.
• Partner closely with the cross-functional quantitative modeling group to provide biological insight, translational context, and critical evaluation supporting PK/PD modeling efforts.
• Influence portfolio progression through generation of high-impact data packages and contributions to regulatory submissions.
• Serve as the in-vivo pharmacology expert on cross-functional project teams, partnering closely with colleagues in Chemistry, Discovery Biology, DMPK, and Toxicology to build cohesive preclinical data sets.
• Communicate scientific strategy, key findings, and program recommendations to cross-functional teams and senior leadership to drive informed decision making.

• Ph.D. in Pharmacology or Cancer Biology, or a related scientific discipline with direct relevance to oncology drug development.
• 5+ years of relevant industry experience in oncology drug discovery and development.
• Demonstrated scientific leadership, strategic thinking, and problem-solving skills in advancing oncology drug discovery programs.
• Deep expertise in tumor biology, RAS signaling pathways, and translational oncology pharmacology.
• Extensive hands-on experience in the design, analysis, and interpretation of in-vivo oncology studies and disease models.
• Strong understanding of translational PK/PD concepts and integration of efficacy, biomarker, and pharmacokinetic data to support translational hypotheses.
• Working knowledge of modeling approaches, including PBPK, QSP, and semi-mechanistic PK/PD frameworks.
• Proven track record of leading, mentoring, and developing scientific talent within collaborative, matrixed research environments.
• Excellent written and verbal communication skills with the ability to effectively communicate complex scientific concepts to both specialist and non-specialist audiences.
• Demonstrated track record of scientific innovation, productivity, and collaboration in a dynamic and fast-paced drug discovery environment.

• Experience with RAS-targeted therapies and diverse oncology therapeutic modalities, including small molecules, antibodies, and antibody-drug conjugates (ADCs).
• Strong theoretical understanding of the concepts, assumptions, and limitations associated with PK/PD and…